FRIDAY, Oct. 6, 2023 — For patients with inadequately controlled type 2 diabetes, once-weekly subcutaneous injections of tirzepatide yield reductions in hemoglobin A1c (HbA1c) and body weight compared with insulin lispro, according to a study…Original Article
Reductions Seen in HbA1c, Body Weight With Once-Weekly Tirzepatide
FRIDAY, Oct. 6, 2023 — For patients with inadequately controlled type 2 diabetes, once-weekly subcutaneous injections of tirzepatide yield reductions in hemoglobin A1c (HbA1c) and body weight compared with insulin lispro, according to a study…